Geron gets green light for human trial of ES cell-derived product

On Jan 23, 2009, the FDA approved the first human trials of embryonic stem (hES) cells. This summer, Geron Corp will begin treating ten patients who have suffered a complete thoracic-level spinal cord injury in a phase 1 multicenter trial. The pioneering therapy is Geron's GRNOPC1 product, whic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2009-03, Vol.27 (3), p.213-214
1. Verfasser:	Alper, Joe
Format:	Artikel
Sprache:	eng
Schlagworte:	Agriculture Bioinformatics Biological products industry Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Clinical trials Clinical Trials, Phase I as Topic - legislation & jurisprudence Clinical Trials, Phase I as Topic - methods Drug Approval Embryonic stem cells Embryonic Stem Cells - transplantation FDA approval Humans Laws, regulations and rules Licensing, certification and accreditation Life Sciences news Obama, Barack Oligodendroglia - transplantation Spinal cord injuries Spinal Cord Injuries - therapy Stem cell research Stem Cell Transplantation - methods Stem cells United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	On Jan 23, 2009, the FDA approved the first human trials of embryonic stem (hES) cells. This summer, Geron Corp will begin treating ten patients who have suffered a complete thoracic-level spinal cord injury in a phase 1 multicenter trial. The pioneering therapy is Geron's GRNOPC1 product, which contains hES cellderived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growthstimulating properties.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt0309-213a